Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)
26 nov. 2018 02h00 HE
|
Hutchison China MediTech Limited
LONDON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the...
Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
16 nov. 2018 02h00 HE
|
Hutchison China MediTech Limited
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited...
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
18 oct. 2018 02h00 HE
|
Hutchison China MediTech Limited
LONDON, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”)...
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
05 sept. 2018 02h00 HE
|
Hutchison China MediTech Limited
– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate® – – Elunate® data published in JAMA demonstrated increased...
Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
27 juil. 2018 02h00 HE
|
Hutchison China MediTech Limited
LONDON, July 27, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) today announces its unaudited financial results for the six months ended June 30, 2018...
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States
23 juil. 2018 02h00 HE
|
Hutchison China MediTech Limited
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic...
Chi-Med to Announce 2018 Half-Year Financial Results
29 juin 2018 02h00 HE
|
Hutchison China MediTech Limited
LONDON, June 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday,...
Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting
04 juin 2018 04h51 HE
|
Hutchison China MediTech Limited
– Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target...
Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
11 mai 2018 07h34 HE
|
Hutchison China MediTech Limited
LONDON, May 11, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of...